CYP1A1 and hepatocellular carcinoma: Our recent in vitro studies with the active derivative of C2 proved it to have virtually equal potency in inducing CYP1A1 activity to TCDD in a rat hepatoma cell line and exhibit similar modelled binding properties to the ligand binding region of the AHR [61].